Literature DB >> 3508177

Preparation and characteristics of dichloromethylene diphosphonate-containing liposomes.

E Classen1, N Van Rooijen.   

Abstract

Dichloromethylene diphosphonate (DMDP), encapsulated in liposomes and administered intravenously in mice, will eliminate all macrophages in spleen and liver. DMDP can be incorporated in liposomes to a maximum of 15 mM, if less than 12 mM is encapsulated not all macrophages will be eliminated (since the animals could not be injected with more liposomes). To determine DMDP content of the liposomes before in vivo administration, an in vitro test system was developed. This method is based on the competition for calcium binding by either DMDP or murexide. Murexide is a metallochromatic indicator which gives a distinct wavelength shift after binding of calcium. The decrease in absorbance at 510 nm of the murexide-calcium complex, due to the addition of DMDP, was used as a reliable (s.d. 5 per cent) value for measurement of DMDP concentrations. The possible use of this system in the study of calcium binding and transport over artificial biomembranes is discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3508177     DOI: 10.3109/02652048609031565

Source DB:  PubMed          Journal:  J Microencapsul        ISSN: 0265-2048            Impact factor:   3.142


  12 in total

1.  Liposomal muramyl dipeptide therapy of experimental M5076 liver metastases in mice.

Authors:  N C Phillips; M S Tsao
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Antigen detection in vivo after immunization with different presentation forms of rabies virus antigen, II. Cellular, but not humoral, systemic immune responses against rabies virus immune-stimulating complexes are macrophage dependent.

Authors:  I J Claassen; A D Osterhaus; M Poelen; N Van Rooijen; E Claassen
Journal:  Immunology       Date:  1998-08       Impact factor: 7.397

3.  Lymphocyte migration in the spleen: the effect of macrophage elimination.

Authors:  G Kraal; H Rodrigues; K Hoeben; N Van Rooijen
Journal:  Immunology       Date:  1989-10       Impact factor: 7.397

4.  The role of macrophages in LPS-induced lethality and tissue injury.

Authors:  P H Groeneveld; E Claassen; C F Kuper; N Van Rooijen
Journal:  Immunology       Date:  1988-03       Impact factor: 7.397

5.  Effects of chronic injection of sphingomyelin-containing liposomes on lymphoid and non-lymphoid cells in the spleen. Transient suppression of marginal zone macrophages.

Authors:  E Claassen; Y Westerhof; B Versluis; N Kors; M Schellekens; N van Rooijen
Journal:  Br J Exp Pathol       Date:  1988-12

6.  Depletion of alveolar macrophages exacerbates respiratory mycoplasmosis in mycoplasma-resistant C57BL mice but not mycoplasma-susceptible C3H mice.

Authors:  J M Hickman-Davis; S M Michalek; J Gibbs-Erwin; J R Lindsey
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

7.  Mechanism of follicular trapping: localization of immune complexes and cell remnants after elimination and repopulation of different spleen cell populations.

Authors:  J D Laman; N Kors; N Van Rooijen; E Claassen
Journal:  Immunology       Date:  1990-09       Impact factor: 7.397

8.  The effects of liposome-encapsulated and free clodronate on the growth of macrophage-like cells in vitro: the role of calcium and iron.

Authors:  J Mönkkönen; T D Heath
Journal:  Calcif Tissue Int       Date:  1993-08       Impact factor: 4.333

9.  Immunomodulation with liposomes: the immune response elicited by liposomes with entrapped dichloromethylene-diphosphonate and surface-associated antigen or hapten.

Authors:  E Claassen; N Kors; N van Rooijen
Journal:  Immunology       Date:  1987-04       Impact factor: 7.397

10.  Reversible depletion of synovial lining cells after intra-articular treatment with liposome-encapsulated dichloromethylene diphosphonate.

Authors:  P L van Lent; L van den Bersselaar; A E van den Hoek; M van de Ende; C D Dijkstra; N van Rooijen; L B van de Putte; W B van den Berg
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.